Abstract
While expression of estrogen receptor (ER) and/or progesterone receptor (PgR) predict for the efficacy of endocrine therapy and Her-2/neu overexpression/amplification predict (imperfectly) for the efficacy of treatment with trastuzumab, neither of these markers has proved effective at predicting antitumor response to other therapies. Overexpression/amplification of Her-2/neu has been one of the most extensively studied predictive parameters, but results have been controversial. In the present article we attempt to review articles published in peer-reviewed medical journals to summarize the evidence concerning Her-2/neu as a predictive factor for the efficacy of endocrine and chemotherapy, respectively. In addition, general limitations of published studies, encouraged and discouraged practices resulting from the available data and future directions which will clarify the role of Her-2/neu as a predictive parameter will be discussed.
Similar content being viewed by others
References
Pietras RJ, Arboleda J, Reese DM, Wongripat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446, 1995
Read LD, Keith Jr D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–3951, 1990
Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318–321, 1992
Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431–437, 1991
Witters LM, Kumar R, Chinchilli VM, Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1–5, 1997
Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W: Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol 23: 70–75, 2002
Fehm T, Maimonis P, Katalinic A, Jager WH: The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55: 33–38, 1998
Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigne SP, Berry DA, Younger J, Panasci LL, Millard F, Dnggan DB, Norton L, Henderson IC: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703–2711, 2001
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nelin CM, DuganM, CarneyW, Allard J: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467–1472, 2002
Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, Robertson JF: Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40: 251–255, 1996
Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antiHer-2/neu as predictive marker S83 estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525, 1997
Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266, 1995
Elledge RM, Green S, Ciocca D, Pagh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7–12, 1998
Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–1226, 1999
Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992
Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018–1023, 1993
Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 37: 347–354, 2001
Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11–18, 1995
Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11: 43–48, 1997
Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, Gluck S: Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 24: 377–384, 1999
Bewick M, Conlon M, Gerard S, Lee H, Parissenti AM, Zhang L, Gluck S, Lafrenie RM: HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 27: 847–853, 2001
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveres B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356–2362, 2000
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19: 1698–1706, 2001
Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD: Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells 20: 32–40, 2002
Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ: Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267–2273, 1998
Kim YS, Konoplev SN, Mentemurro F, Hoy E, Smith TL, Ronden G, Champlin RE, Sahin AA, Veno NT: HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7: 4008–4012, 2001
Luftner D, Schnabel S, Possinger K: c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers 14: 55–59, 1999
Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM: Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917–922, 1997
Revillion F, Hebbar M, Bonneterre J, Peyrat JP: Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 32A: 231–234, 1996
Sjostrom J, Krajewski S, Franssila K, Niskanen E, Wasenius VM, Nodling S, Reed JC, Blomqvist C: A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 78: 812–815, 1998
Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Molmstrom P, Ostenstad B, Wist E, Valvere V, Bergh J, Skiold-Petterson D, Saksela E, Blomqvist C: C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38: 535–542, 2002
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol Z 20: 2319–2326, 2002
Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CH: Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 65: 271–274, 1992
Piccart MJ, de Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux L, Arrigo L, Cantraine F, Heuson JC: Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 62: 2501–2506, 1988
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Welmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361–1370, 1998
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Radenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056, 1992
Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM: Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 84: 354–359, 1999
Menard S, Valagussa, Pilotti S, Gianni L, Biganzoli E, Borecchi P, Tomasie G, Casalini P, Marubini E, Colneghi MI, Cascinelli N, Bonadanna G: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 19: 329–335, 2001
Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Tembe S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456–1466, 1996
Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547, 1997
Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 34: 499–504, 1995
Narita T, Funahashi H, Satoh Y, Takagi H: C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97–102, 1993
Molina R, Jo J, Filella X, Zanan G, Pahisq J, Mano ZM, Farrus B, Lattre ML, Gimenez N, Hage M, Estape J, Balleste AM: C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 16: 2295–2300, 1996
Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A: Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 78: 267–272, 1996
Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43: 87–95, 1997
Ciocca DR, Fujimura FK, Tandon AK et al.: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84: 1279–1282, 1992
Grunt TW, Saceda M, Martin MB et al.: Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560–567, 1995
Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63–72, 1996
Coates A, Gebski V, Bishop JF et al.: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1497, 1987
Bast Jr RC, Ravdin P, Hayes DF et al.: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865–1878, 2001
Leitzel K, Teramoto Y, Konrad K et al.: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Köstler, W.J., Zielinski, C.C. Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer. Breast Cancer Res Treat 81 (Suppl 1), 73–84 (2003). https://doi.org/10.1023/A:1026329109327
Issue Date:
DOI: https://doi.org/10.1023/A:1026329109327